Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529515 · ClinicalTrials.gov registry record · Phase 3
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 509
- Enrollment target
NCT01529515 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 509 participants.
The verdict
NCT01529515, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 509 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
Interventions
- DRUG PP3M 350 mg eq.
- DRUG PP3M 525 mg eq.
- DRUG PP3M 175 mg eq.
- DRUG PP3M 263 mg eq.
- DRUG Placebo (20% Intralipid emulsion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529515
The ClinicalTrials.gov registry entry for NCT01529515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PP3M 350 mg eq. is the first listed.
NCT01529515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529515 about?
NCT01529515 is a clinical study titled "A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia". The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
What is the current status of trial NCT01529515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 509 participants. The study started on 2012-05. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01529515?
The interventions under investigation include: PP3M 350 mg eq. (DRUG), PP3M 525 mg eq. (DRUG), PP3M 175 mg eq. (DRUG), PP3M 263 mg eq. (DRUG), Placebo (20% Intralipid emulsion) (DRUG).
Who is sponsoring clinical trial NCT01529515?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.